BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

California Verdict Finds Warner-Lambert (PFE) Not Liable In Rezulin Trial


10/19/2005 5:11:32 PM

NEW YORK, May 27 /PRNewswire-FirstCall/ -- A California jury today unanimously found that the Warner-Lambert Company, which supplied the prescription diabetes drug Rezulin before Pfizer acquired Warner-Lambert in June 2000, was not liable for the deaths of Manuel Cervantes and Lupe Contreras and the illness of Leonard Clinkenbeard, Pfizer said.

The trial-which began on April 12-took place in California Superior Court, Los Angeles County. The jury, in a 12-0 decision, determined that the facts in the case did not support the plaintiff's claims that Rezulin caused or contributed to the deaths or liver disease of the three long-time diabetes sufferers.

Diabetes is a serious life-threatening illness that affects over 17 million Americans. Rezulin, which was approved by the FDA in 1997, was voluntarily withdrawn from the market in March 2000 after two newer drugs became available that were comparable in effectiveness and that appeared to have fewer side effects.

Photo: A free corporate logo to accompany this story is availableimmediately via Wieck Photo Database to any media with telephoto receiver orelectronic darkroom, PC or Macintosh, that can accept overhead transmissions.To retrieve a logo, please call 972-392-0888. Pfizer Inc

CONTACT: Bryant Haskins, +1-212-733-8719 for Pfizer

Company News On-Call: Pfizer's press releases are available through PRNewswire's Company News On-Call service on PRN's Web Site. Visithttp://www.prnewswire.com/comp/688250.html

Company News On-Call: http://www.prnewswire.com/comp/688250.html



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES